Clovis Oncology to offer $225M in convertible senior notes to investors

Clovis Oncology to offer $225M in convertible senior notes to investors

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced it intends to offer $225 million aggregate principal amount of its convertible senior notes due 2024 in a private placement to... Read More

Thursday August 8, 2019 0 comments Tags: Boulder, Clovis Oncology

Clovis Oncology names Ginger Graham board chair

Clovis Oncology names Ginger Graham board chair

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced the appointment of Ginger L. Graham as chair of the companys board of directors following the retirement of former board chair Dr. ... Read More

Friday June 7, 2019 0 comments Tags: Boulder, Clovis Oncology, Ginger Graham, Patrick J. Mahaffy

Clovis Oncology to receive $175M to fund company’s largest clinical trial

Clovis Oncology to receive $175M to fund company’s largest clinical trial

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) today announced it has entered into an agreement for up to $175 million in non-dilutive clinical trial financing with certain affiliates of TPG... Read More

Thursday May 2, 2019 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy, TPG Sixth Street Partners, ATHENA study, Rubraca

Clovis Oncology announces interim results for drug treating pancreatic cancer

Clovis Oncology announces interim results for drug treating pancreatic cancer

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced interim results from an investigator-initiated Phase 2 trial of Rubraca (rucaparib) in platinum-sensitive patients with advanced... Read More

Tuesday April 2, 2019 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy, Rubraca

Clovis Oncology: Rubraca now available in Germany for ovarian cancer therapy

Clovis Oncology: Rubraca now available in Germany for ovarian cancer therapy

BOULDER MUNICH -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced Rubraca (rucaparib) is now available by prescription in Germany as monotherapy for the maintenance treatment of adults with... Read More

Tuesday March 5, 2019 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy

Clovis Oncology announces European Commission OK of Rubraca for ovarian cancer

Clovis Oncology announces European Commission OK of Rubraca for ovarian cancer

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the European Commission (EC) has approved the use of Rubraca(rucaparib) for treatment of ovarian cancer. Specifically, the... Read More

Monday January 28, 2019 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy, Rubraca, Rucaparib

Clovis Oncology announces positive hearing for Rubraca in Europe

Clovis Oncology announces positive hearing for Rubraca in Europe

BOULDER -- Clovis Oncology, Inc. (NASDAQ:CLVS) today announced after opposition proceedings at The Hague, Netherlands, that the European Patent Office upheld claims of European Patent 2534153... Read More

Wednesday December 5, 2018 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy, Rucaparib

Clovis Oncology announces second patent for Rucaparib high dose

Clovis Oncology announces second patent for Rucaparib high dose

BOULDER -- Clovis Oncology , Inc. (NASDAQ:CLVS) today announced the United States Patent and Trademark Office issued United States Patent 10,130,636 with claims directed to methods of treating... Read More

Tuesday November 20, 2018 0 comments Tags: Boulder, Clovis Oncology, Rucaparib, Patrick J. Mahaffy